BCL2L1 and benign prostatic hyperplasia: Correspondingly, Bcl-xL, one of the members of the Bcl-2 family, showed an increased expression in the BPH group as compared to its expression in the control group, whereas administration of Fina, BC 50, and BC 100 attenuated the effect of TP treatment.